Document Detail


Comparison of clofezone and diclofenac in the treatment of out-patients suffering from activated (painful) osteoarthrosis.
MedLine Citation:
PMID:  153679     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The effectiveness and acceptability of clofezone (Perclusone) were compared with those of diclofenac in a placebo-controlled, double-blind, cross-over trial on a group of 29 out-patients suffering from osteoarthrosis of the knee or hip. Clofezone was given at a daily dosage of 1200 mg during the first week and 600 mg during the second week; the corresponding dosages of diclofenac were 150 mg and 75 mg. The duration of the trial was 6 weeks. In order to wash out previous medication, a placebo was given for one week before and after each medication period. Eight of the patients stopped taking their drug after 1--3 weeks, namely 5 in the clofezone group and 3 in the diclofenac group, while one patient stopped taking the placebo. The principal reason for these stoppages was gastrointestinal intolerance. These 9 patients were disregarded in the evaluation of the trial results. This evaluation on the remaining 20 patients showed that clofezone brought about a significant improvement in respect of pain (both at rest and during movement), inflammation and mobility after two weeks' application. In the diclofenac group the only significant improvement after the same period was in respect of pain during movement. Statistical comparison of the two groups showed that the reduction in pain during movement and in inflammation was significantly greater under clofezone than under diclofenac and that clofezone had the longer-lasting action. These findings are discussed in the light of the kinetic characteristics of the two drugs and of the mild antidepressant properties of clofezone. There was no significant difference between the two drugs as regards tolerance.
Authors:
D Brackertz
Related Documents :
16511939 - Gastrointestinal prophylactic therapy among patients with arthritis treated by rheumato...
2776469 - A double-blind comparison of flurbiprofen with diflunisal in the treatment of acute ank...
23551409 - Effects of yangxue qingnao granules on chronic cerebral circulation insufficiency: a ra...
11695249 - Cox-2 inhibitors and the cardiovascular system.
8330469 - Adverse effects of low-dose aspirin in a healthy elderly population.
14620099 - Adjunctive treatment of decompression illness with a non-steroidal anti-inflammatory dr...
20403099 - Impact of functional bowel symptoms on quality of life and fatigue in quiescent crohn d...
18428079 - Outcomes in major depressive disorder: the evolving concept of remission and its implic...
22723129 - Prevalence and clinical features of newly diagnosed generalized anxiety disorder patien...
Publication Detail:
Type:  Clinical Trial; Comparative Study; Controlled Clinical Trial; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Zeitschrift für Rheumatologie     Volume:  37     ISSN:  0340-1855     ISO Abbreviation:  Z Rheumatol     Publication Date:    1978 Sep-Oct
Date Detail:
Created Date:  1979-03-13     Completed Date:  1979-03-13     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0414162     Medline TA:  Z Rheumatol     Country:  GERMANY, WEST    
Other Details:
Languages:  eng     Pagination:  342-9     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Ambulatory Care
Clinical Trials as Topic
Diclofenac / therapeutic use*
Double-Blind Method
Drug Evaluation
Drug Tolerance
Female
Humans
Male
Middle Aged
Osteoarthritis / drug therapy*
Phenylacetates / therapeutic use*
Phenylbutazone / analogs & derivatives*,  therapeutic use*
Chemical
Reg. No./Substance:
0/Phenylacetates; 15307-86-5/Diclofenac; 50-33-9/Phenylbutazone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Animal experiment studies on the effect of intra-articular injections of antiphlogistic-antirheumati...
Next Document:  Immunologic donor-recipient matching in living kidney transplantation